News

Deal Announcements

DeuteRx Secures Seed Venture Capital Funds

Friday, October 2, 2015 5:44:00 AM PDT | VentureDeal
   Andover, Massachusetts  --  Biotechnology company DeuteRx has landed $2.8 million in seed stage venture capital financing.

DeuteRx says that it is "dedicated to improving racemic small molecule marketed drugs and drug candidates intended for patients across multiple therapeutic indications."

Investors in the financing were not disclosed.

DeuteRx said it will use the funds to advance its lead program, DRX-065, into human clinical trials for the potential treatment of adrenoleukodystrophy (ALD).

The company is a spin-out from Deuteria Pharmaceuticals and is headed by Pres. and CEO Sheila DeWitt.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1